Pomegra
Boulevard Bio launched August 12 with $65 million from Deerfield Management to advance a pipeline of multi-specific antibodies against B cell-driven autoimmune diseases, led by a bispecific targeting IgA nephropathy.
Key Takeaways
- Boulevard Bio raised $65M via equity and convertible notes, incubated inside Deerfield's internal R&D engine 3DC
- Lead candidate BLVD101, a dual BAFF/APRIL bispecific, showed IgA suppression in Phase 1 with a quarterly dosing schedule
- A second asset, trispecific T-cell engager BLVD201, was in-licensed from METiS TechBio in June 2026 for a $20M upfront payment
Lead
Boulevard Bio emerged from stealth on August 12, 2026, disclosing $65 million in combined equity capital and convertible notes - all from Deerfield Management and its affiliates. The San Francisco-based immunology startup was incubated within 3DC, Deerfield's internal therapeutics development engine, a structure that allowed it to arrive at its public debut with Phase 1 human data already in hand rather than the typical preclinical assets most stealth launches carry.
What Does Boulevard Bio Actually Do?
The company's thesis is that B cells are the root driver of a cluster of serious autoimmune conditions that existing therapies address incompletely. Its approach is multi-specific antibodies - molecules engineered to hit more than one molecular target simultaneously - rather than the single-target biologics that dominate the current autoimmune market.
The lead asset, BLVD101, is a dual BAFF/APRIL-targeting bispecific antibody. Both BAFF and APRIL are cytokines that sustain B cell survival; blocking them together is intended to suppress the abnormal IgA antibodies that cause IgA nephropathy (IgAN), a progressive kidney disease with limited treatment options. Phase 1 data in healthy volunteers showed meaningful IgA suppression. The dosing interval - quarterly injections - compares favorably to atacicept, a competing BAFF/APRIL inhibitor that currently requires weekly administration.
A third candidate, the trispecific T-cell engager BLVD201, was added to the pipeline just two months before launch via an in-licensing deal with METiS TechBio for a $20 million upfront payment. It is designed to induce what the company calls immune reset in severe autoimmune disease, a more ambitious biological objective than symptomatic control.
Why Did Deerfield Fund the Entire Round?
Single-investor launches at this size are unusual. The explanation is structural: Boulevard Bio did not raise from Deerfield, it was built by Deerfield. The company was developed inside 3DC, Deerfield's proprietary drug creation unit, giving the fund early control over target selection, molecule design, and clinical strategy before any outside capital entered the picture.
The arrangement means Deerfield carries concentrated exposure with no co-investors to share downside risk. It also means Boulevard Bio's clinical and financial roadmap is closely aligned with a single institution's interests - a dynamic that could complicate future syndication if the company seeks outside investors for a Series B.
Who Is Running the Company?
Chief Executive Officer Mahesh Karande leads operations. Chief Medical Officer Neil Solomons, MD oversees clinical development. The scientific co-founders include Prof. Georg Schett, MD, a prominent researcher in immune reset strategies, and Prof. Jonathan Barratt, PhD, FRCP, whose work on IgA nephropathy spans decades.
Brian Chow, PhD, Managing Director at Deerfield, chairs the board. Frank Nestle, MD, a Deerfield partner and 3DC chief executive, holds a seat as scientific co-founder - a configuration that keeps Deerfield's influence embedded in both governance and scientific direction simultaneously.
What Does This Signal for the IgAN Space?
IgA nephropathy has become one of the more competitive targets in nephrology after a series of approvals and late-stage readouts in recent years. The fact that Boulevard Bio enters with bispecific rather than monospecific biology, and with quarterly rather than weekly dosing as a potential differentiator, reflects how quickly the field has moved past first-generation mechanisms.
The in-licensing of BLVD201 a month before launch suggests the company is already thinking past IgAN toward broader autoimmune indications where T-cell-mediated immune reset could matter - rheumatoid arthritis, lupus, and inflammatory myopathies have all been cited as potential applications by researchers working in this area.
Outlook
Boulevard Bio enters the public arena better capitalized than most stealth exits and with clinical proof-of-concept data that removes at least one layer of early-stage risk. The concentrated Deerfield ownership is both a strength and a constraint - it accelerates decision-making but narrows the capital pool. The next meaningful test is Phase 2 data for BLVD101, which will determine whether the quarterly dosing advantage and the BAFF/APRIL dual-block translate into efficacy that justifies advancement against an increasingly crowded IgAN field.
